These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3897730)

  • 21. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Non-specific killer cells in tumor immune response].
    Kumagai K
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):726-33. PubMed ID: 3985642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin.
    Mazumder A; Grimm EA; Rosenberg SA
    J Immunol; 1983 Feb; 130(2):958-64. PubMed ID: 6848602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
    Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
    Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
    Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
    Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
    Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
    Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
    Da Costa ML; Redmond HP; Bouchier-Hayes DJ
    J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.
    Hefeneider SH; Conlon PJ; Henney CS; Gillis S
    J Immunol; 1983 Jan; 130(1):222-7. PubMed ID: 6600178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of malignant tumors by interleukin 2 and LAK cells].
    Degos L
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):119-22. PubMed ID: 3260373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.